Related Experiment Video

Updated: Dec 20, 2025

Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

11.3K

B-type natriuretic peptide and outcome in patients with apical hypertrophic cardiomyopathy

Shota Shirotani1, Yuichiro Minami1, Chihiro Saito1

  • 1Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.

Journal of Cardiology
|May 23, 2020
PubMed

Insights

Elevated B-type natriuretic peptide (BNP) levels in apical hypertrophic cardiomyopathy (HCM) patients predict adverse outcomes. High BNP levels independently indicate a greater risk of combined endpoints in this population.

Area of Science:

  • Cardiology
  • Genetics
  • Biomarkers

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease.
  • The apical phenotype of HCM presents unique clinical challenges.
  • Prognostic value of B-type natriuretic peptide (BNP) in apical HCM is not well-established.

Purpose of the Study:

  • To investigate the association between B-type natriuretic peptide (BNP) levels and clinical outcomes in patients with apical hypertrophic cardiomyopathy (HCM).
  • To determine if BNP can serve as a prognostic biomarker for adverse events in this specific HCM phenotype.

Main Methods:

  • Retrospective analysis of 144 patients with apical HCM phenotype.
  • Measurement of plasma BNP levels at initial evaluation.
  • Long-term follow-up to assess HCM-related adverse outcomes.

Main Results:

  • Median BNP level was 188.5 pg/mL.
  • A BNP cutoff of 226.0 pg/mL predicted adverse outcomes (log-rank p<0.001).
  • High BNP levels (≥226.0 pg/mL) were an independent determinant of adverse events (aHR: 3.71; p=0.002).

Conclusions:

  • B-type natriuretic peptide (BNP) measurement can aid in risk stratification for patients with apical HCM.
  • Elevated BNP levels are associated with increased risk of adverse outcomes in apical HCM.
  • BNP serves as a valuable prognostic tool for apical HCM management.
Abstract

Keywords:
ApicalB-type natriuretic peptideHypertrophic cardiomyopathyOutcome

More Related Videos

Quantitative Micro-CT Analysis of Aortopathy in a Mouse Model of &#946;-aminopropionitrile-induced Aortic Aneurysm and Dissection06:46

Quantitative Micro-CT Analysis of Aortopathy in a Mouse Model of β-aminopropionitrile-induced Aortic Aneurysm and Dissection

Published on: July 16, 2018

9.9K
Murine Model of Thoracic Aortic Dissection Induced by Oral &#946;-Aminopropionitrile and Subcutaneous Angiotensin II Infusion05:31

Murine Model of Thoracic Aortic Dissection Induced by Oral β-Aminopropionitrile and Subcutaneous Angiotensin II Infusion

Published on: May 16, 2025

683

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
577
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
434
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
801
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
277
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
329
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
216